ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 29.55M shares rose 6.6% year over year, ahead of the +4.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at +5.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.6% holds above the trailing-twelve-month pace of +4.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
29.55M+4.3% QoQ
Last fiscal yearDec 2025
28.32M+4.8% YoY
LTMMar 2026
28.64M+4.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.6%——
1 year+4.8%——
3-year CAGR+5.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
28.32M USD
Year-over-year change
+4.8%
4-year CAGR
+8.1%

Weighted Avg Shares vs competitors

How CLPT compares with its peers on the latest reported figures

  • CLPT's LTM Mar 2026 weighted avg shares of 28.64M shares is the lowest of the 10 companies compared; the peer median is 98.1M shares.
  • Its year-over-year change of +4.3% is the 3rd highest of 10, against a peer median of +2.7%.
  • Over three fiscal years its annual growth of +5.4% compares with a peer median of +8.4%.
CLPT Competitors Peer median
Weighted Avg Shares for CLPT and competitors
Company Period LTM YoY 3-year CAGR
LABStandard BioTools Inc.LTM Mar 2026384.09M +2.7%+69.5%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026264.94M +21.2%+12.1%
SNDLSNDL Inc.LTM Mar 2026259.55M -1.2%+3.9%
CTKBCytek Biosciences, Inc.LTM Mar 2026127.84M -1.7%-1.7%
CMPSCOMPASS Pathways plcLTM Mar 202698.1M +33.3%+30.1%
AVNSAvanos Medical, Inc.LTM Mar 202646.33M +0.7%-0.4%
SIBNSI-BONE, Inc.LTM Mar 202643.36M +3.6%+8.4%
VREXVarex Imaging CorporationLTM Apr 202641.7M +1.6%+1.3%
OFIXOrthofix Medical Inc.LTM Mar 202639.93M +3.4%+25.7%
CLPTClearPoint Neuro, Inc.LTM Mar 202628.64M +4.3%+5.4%
Peer median (excluding CLPT) 98.1M+2.7%+8.4%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.3M20.55M23.96M31.39M36.97M
Cost of Revenue5.18M7.02M10.34M12.27M14.28M
Gross Profit11.12M13.53M13.61M19.12M22.69M
Gross Margin68.2%65.8%56.8%60.9%61.4%
Research & Development9.28M10.89M11.71M12.39M13.9M
Selling, General & Admin15.22M18.97M24.35M26.48M32.96M
Operating Expenses24.5M29.86M36.06M38.87M46.86M
Depreciation & Amortization692K777K1.46M1.9M2.24M
EBITDA(12.75M)(15.58M)(20.63M)(17.01M)(20.86M)
EBITDA Margin-78.2%-75.8%-86.1%-54.2%-56.4%
Operating Income(13.37M)(16.33M)(22.45M)(19.75M)(24.16M)
Operating Margin-82.1%-79.5%-93.7%-62.9%-65.4%
Interest Income00386K872K1.21M
Interest Expense973K81K002.39M
Other Income / Expenses(1.04M)(103K)357K832K(1.32M)
Income Before Tax(14.41M)(16.44M)(22.09M)(18.91M)(25.49M)
Pre-Tax Margin-88.4%-80.0%-92.2%-60.3%-68.9%
Income Tax Expense000055K
Net Income(14.41M)(16.44M)(22.09M)(18.91M)(25.54M)
Net Margin-88.4%-80.0%-92.2%-60.3%-69.1%
EPS (Basic)(0.69)(0.68)(0.90)(0.70)(0.90)
EPS (Diluted)(0.69)(0.68)(0.90)(0.70)(0.90)
Weighted Avg Shares20.73M24.18M24.61M27.03M28.32M
Weighted Avg Shares (Diluted)20.73M24.18M24.61M27.03M28.32M

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.